These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

635 related articles for article (PubMed ID: 33219281)

  • 1. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence.
    Alicic RZ; Cox EJ; Neumiller JJ; Tuttle KR
    Nat Rev Nephrol; 2021 Apr; 17(4):227-244. PubMed ID: 33219281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Diabetes Medications Targeting the Incretin System on the Kidney.
    MacIsaac RJ; Thomas MC
    Clin J Am Soc Nephrol; 2018 Feb; 13(2):321-323. PubMed ID: 29321176
    [No Abstract]   [Full Text] [Related]  

  • 3. Renoprotective effects of incretin-based drugs: A novel pleiotropic effect of dipeptidyl peptidase-4 inhibitor.
    Kodera R; Shikata K
    J Diabetes Investig; 2016 Jan; 7(1):29-31. PubMed ID: 26816598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiology and pathophysiology of incretins in the kidney.
    von Websky K; Reichetzeder C; Hocher B
    Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):54-60. PubMed ID: 24257158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?
    Muskiet MH; Smits MM; Morsink LM; Diamant M
    Nat Rev Nephrol; 2014 Feb; 10(2):88-103. PubMed ID: 24375052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
    Russell S
    Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GLP-1 Receptor Agonists in Diabetic Kidney Disease.
    Michos ED; Tuttle KR
    Clin J Am Soc Nephrol; 2021 Oct; 16(10):1578-1580. PubMed ID: 33849933
    [No Abstract]   [Full Text] [Related]  

  • 8. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
    Sloan LA
    J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pleiotropic effects of incretins and antidiabetic drugs with incretine mechanism].
    Winkler G
    Orv Hetil; 2013 Feb; 154(7):248-55. PubMed ID: 23395788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of incretin-based therapies in the management of type 2 diabetes.
    Bandyopadhyay P
    Drug News Perspect; 2009 Nov; 22(9):559-67. PubMed ID: 20072733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes.
    Muskiet MHA; Tonneijck L; Smits MM; van Baar MJB; Kramer MHH; Hoorn EJ; Joles JA; van Raalte DH
    Nat Rev Nephrol; 2017 Oct; 13(10):605-628. PubMed ID: 28869249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretins: their physiology and application in the treatment of diabetes mellitus.
    Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S
    Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential for renoprotection with incretin-based drugs.
    Tanaka T; Higashijima Y; Wada T; Nangaku M
    Kidney Int; 2014 Oct; 86(4):701-11. PubMed ID: 25007170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New oral hypoglycemic drugs in diabetic kidney disease].
    Dylewska M; Graczyk M
    Wiad Lek; 2017; 70(6 pt 2):1193-1196. PubMed ID: 29533912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis.
    Howse PM; Chibrikova LN; Twells LK; Barrett BJ; Gamble JM
    Am J Kidney Dis; 2016 Nov; 68(5):733-742. PubMed ID: 27528374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renoprotection in diabetic kidney disease: can incretin-based therapies deliver?
    van Baar MJB; van Raalte DH
    Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):103-111. PubMed ID: 31714285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Not only incretins for diabetic kidney disease-beneficial effects by DPP-4 inhibitors.
    Nangaku M; Wanner C
    Kidney Int; 2021 Feb; 99(2):318-322. PubMed ID: 33509354
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.
    Scheen AJ
    Diabetes Metab; 2019 Apr; 45(2):110-121. PubMed ID: 30477733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of glucose-lowering therapies on diabetic kidney disease.
    Agrawal V; Giri C; Solomon RJ
    Curr Diabetes Rev; 2015; 11(3):191-200. PubMed ID: 25824237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.